As less than half of those cases expressed appreciable CEACAM6 levels and since CEACAM6 expression was not an inclusion criterion in our trial, patient heterogeneity in tumor CEACAM6 may have explained the modest efficacy we observed, since without sufficient CEACAM6, L-DOS47 could not bind and alkalinize the TME. Here, CEACAM6 is linked to neoplasm.